Blood
Articles in this Issue
Can less differentiation drive CARs to success?
Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic cell proliferation
HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma
Abstract CD30-directed chimeric antigen receptor T-cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable...
The decline of transplant for relapsed myeloma
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis
Abstract Desmopressin (1-desamino-8-d-arginine vasopressin [DDAVP]) can be used to prevent or stop bleeding. However, large interindividual variability is observed in DDAVP response...
Dual targeting of EZH2 and DOT1L in DLBCL
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Abstract The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally t...
Determinants of DDAVP response
How I treat patients with low-risk polycythemia vera who require cytoreduction
Abstract Polycythemia vera (PV) was first described by Louis Henri Vaquez in 1892. It is a chronic hematological malignancy that affects both older and young patients. Perhaps becaus...
A rare case of nodal hairy cell leukemia exhibiting characteristic morphological and immunohistochemical features
How I diagnose and treat systemic mastocytosis with an associated hematologic neoplasm
Abstract Over the last decade significant advances have been made by honing the diagnostic evaluation and the significance of molecular profiles in patients with nonadvanced and adva...
Introduction to a How I Treat series on myeloproliferative neoplasms
The biologic, clinical, and molecular heterogeneity of myeloproliferative neoplasms (MPNs), as well as the unique treatment goals of individuals, often lead to a melding of data-driven algorithms with...
How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions
Abstract The fifth edition of the World Health Organization (WHO) classification and the International Consensus Classification (ICC) both include a category "myeloid/lymphoid neopla...
How I individualize selection of JAK inhibitors for patients with myelofibrosis
Abstract The advent of Janus kinase inhibitors (JAKis) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manif...
How I treat anemia in myelofibrosis
Abstract Anemia is a common consequence of myelofibrosis. The treatment of myelofibrosis-associated anemia is complicated by a multifactorial pathobiology and a lack of therapies tha...
How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms
Abstract Arterial and venous thromboses are the most significant complications in patients with myeloproliferative neoplasms (MPNs), with the primary treatment goal being thrombotic...
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma
Abstract Differentiation of antigen-activated B cells into proproliferative germinal center (GC) B cells depends on the activity of the transcription factors myelocytoma (MYC) and...